The main reason for the downturn in Moderna’s stock is a significant drop in the demand for its COVID-19 vaccine.

First, let's back up a bit and take a look at the Moderna story, from the glory days of a few years ago to its troubles today ...

Moderna vaulted to the forefront of biotech, becoming a major pillar of the region’s economy. But Robert F. Kennedy Jr.’s ...

Moderna Inc. is in discussions with large drugmakers and financial firms to get funding for some late-stage vaccine trials as ...

The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...

Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA / ACCESS ...

Moderna's shares fell 2.5% before the bell on Friday, on concerns whether a new CDC advisory panel would back the use of the ...

Dwight Morrow was thrilled to land a job at Moderna in June 2023 after its blockbuster Covid-19 vaccine had turned the once-obscure Cambridge biotech into a household name. Morrow, a molecular and ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

The agency’s decision to clear Moderna’s shot for use in certain younger adults is a much-needed win for a company that’s ...